Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-labeled CMV pp65-LAMP mRNA-pulsed autologous dendritic cells
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
111In-labeled dendritic cells are a diagnostic and therapeutic component of the ELEVATE clinical trial (NCT02366728) for newly diagnosed glioblastoma. These autologous dendritic cells are pulsed with mRNA encoding the Cytomegalovirus (CMV) pp65 antigen fused to a Lysosomal-Associated Membrane Protein (LAMP) signal and contain Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). The cells are labeled with the radioisotope Indium-111 (111In) to allow for tracking of their migration to inguinal lymph nodes via SPECT/CT imaging. This cell-based immunotherapy aims to stimulate a T-cell mediated immune response against glioblastoma cells, which frequently express the CMV pp65 antigen. The trial specifically investigates whether pre-conditioning the injection site with tetanus-diphtheria (Td) toxoid enhances the migration and clinical efficacy of the vaccine.
- Other names
- 111In-labeled dendritic cellsIndium-111 labeled dendritic cellsIndium111 labeled dendritic cellsIndium 111 labeled dendritic cellsCMV-specific dendritic cell vaccinepp65-LAMP mRNA-pulsed DCspp-65-LAMP mRNA-pulsed DCspp 65-LAMP mRNA-pulsed DCs
Beyond the preview
Go deeper on 111In-labeled CMV pp65-LAMP mRNA-pulsed autologous dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-labeled CMV pp65-LAMP mRNA-pulsed autologous dendritic cells.